CagriSema misses noninferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% iPharmaCenter Cagrilintide, an amylin analog, enhances the weight loss effects of semaglutide or tirzepatide by slowing gastric emptying, suppressing glucagon, and reducing appetite. It works synergistically with Cagrilintide is an amylin analogue that helps regulate appetite. In a randomized trial of over 3400 patients who were overweight or obese and had 1 weight related complication, individuals assigned to a combination Presented at the ADA 85th Scientific Sessions: In the REDEFINE 1 phase 3a trial, semaglutide at a dose of 2.4 mg with cagrilintide at a dose of 2.4 mg led to significant